Right Ventricular Function, Clinical Outcomes, and Effect of Vutrisiran in Transthyretin Amyloidosis With Cardiomyopathy: Insights from the HELIOS-B Trial

MedXY Editorial Team•Aug 28, 2026•Cardiology

Right ventricular dysfunction in transthyretin amyloidosis cardiomyopathy (ATTR-CM) is highly prevalent and better identified by RV free wall strain (RVFWS) compared to conventional echocardiographic measures.
RVFWS and the ratio of RVFWS to pulmonary artery systolic pressure (RVFWS/PASP) independently predict all-cause mortality and recurrent cardiovascular events, beyond established risk factors and left ventricular function.
Vutrisiran, an RNA interference therapeutic, stabilizes RV function measured by RVFWS and improves RVFWS/PASP over 30 months, reflecting beneficial cardiac remodeling in ATTR-CM.
Conventional RV functional indices such as RV S’ and RV fractional area change (FAC) underestimate RV dysfunction and lack robust prognostic value in ATTR-CM.

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Right ventricular dysfunction in transthyretin amyloidosis cardiomyopathy (ATTR-CM) is highly prevalent and better identified by RV free wall strain (RVFWS) compared to conventional echocardiographic measures.
RVFWS and the ratio of RVFWS to pulmonary artery systolic pressure (RVFWS/PASP) independently predict all-cause mortality and recurrent cardiovascular events, beyond established risk factors and left ventricular function.
Vutrisiran, an RNA interference therapeutic, stabilizes RV function measured by RVFWS and improves RVFWS/PASP over 30 months, reflecting beneficial cardiac remodeling in ATTR-CM.
Conventional RV functional indices such as RV S’ and RV fractional area change (FAC) underestimate RV dysfunction and lack robust prognostic value in ATTR-CM.